ENERGY & COMMERCE MEDICARE DRUG BENEFIT WILL BE "FULL,"
Executive Summary
ENERGY & COMMERCE MEDICARE DRUG BENEFIT WILL BE "FULL," BIO predicts: "We expect there will be a full Medicare benefit in the Energy & Commerce bill, not a new type of benefit, not a catastrophic benefit, not a limited benefit only applying to certain people," Biotechnology Industry Organization VP-Government Relations Chuck Ludlam said at an April 12 Biotech Tuesday meeting. BIO, he emphasized, "endorses a full Medicare drug benefit -- we support it, we want it, we are not supporting a means-tested or a catastrophic benefit."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth